Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 20/20 | 0.70 |
| ▸ | CNR1 | P21554 | 7/20 | 0.70 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091977 | 0.98 | CNR2 (0.70) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5104557 | 0.91 | CNR2 (0.84) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5098449 | 0.91 | CNR2 (0.84) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL14097660 | 0.91 | CNR2 (0.84) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5104454 | 0.90 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL5095710 | 0.89 | CNR2 (0.84) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5490824 | 0.89 | CNR2 (0.84) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5104711 | 0.89 | CNR2 (0.77) | CNR2CNR1 | |
| SCHEMBL14097695 | 0.89 | CNR2 (0.61) | CNR2CNR1BCHEOPRM1ACHE | |
| SCHEMBL5104499 | 0.89 | CNR2 (0.61) | CNR2CNR1BCHEOPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | claimed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | claimed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-7407968-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105893-A1 | Novel Compounds | ASTRAZENECA AB R&D HEADQUARTERS GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105893-A1 | Novel Compounds | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885BCHE 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.